Computational modeling identifies effective phenylpropanoid derivatives against intracellular Trypanosoma cruzi, suggesting new treatments.
Previous investigations have demonstrated that n-hexacosyl p-coumarate, a natural product isolated from the Brazilian plant Baccharis sphenophylla, exhibits activity against the extracellular (trypomastigote) forms of Trypanosoma cruzi. Structural modification of this compound led to the synthesis of the n-hexyl p-coumarate derivative, which showed significantly improved bioactivity, achieving an EC₅₀ value of 1.7 μM and a selectivity index of 71 against trypomastigote forms. However, when tested against intracellular amastigote forms, the compound displayed only moderate activity (EC₅₀ = 13 μM) and some cytotoxicity (CC₅₀ = 120 μM). To enhance efficacy and minimize toxicity, the double bond between C-7 and C-8 was reduced to a single bond, affording a series of phloretic acid derivatives ( 3a–3f ). These derivatives were synthesized via Fischer esterification and evaluated for their in silico ADMET properties, which indicated improved drug-likeness profiles. Notably, phloretic acid derivatives exhibited substantially lower cytotoxicity (CC₅₀ > 200 μM) compared with the p-coumaric acid analogues, while maintaining potent activity against amastigote forms (EC₅₀ ≈ 10 μM), comparable to the reference drug benznidazole. A structure–activity relationship (SAR) analysis based on machine learning was performed using a deep neural network (DNN) model combined with SHAP interpretation, allowing identification of key molecular fragments influencing predicted EC₅₀ values, as well as their correlation with molecular flexibility and lipophilicity. Collectively, these results underscore the potential of phloretic acid derivatives as lead candidates for the development of new anti- T. cruzi agents. • n -Hexyl p -coumarate showed potent bioactivity against trypomastigote forms of Trypanosoma cruzi but reduced potential against intracellular amastigotes. • To enhance efficacy and minimize toxicity, a series of floretic acid derivatives ( 3a–3f ) were synthesized and evaluated for their in silico ADMET properties, which indicated improved drug-likeness profiles. • Floretic acid derivatives ( 3a–3f ) exhibited substantially lower cytotoxicity (CC₅₀ > 200 μM) and displayed potent activity against amastigotes (EC₅₀ ≈ 10 μM), comparable to the reference drug benznidazole. • SAR analysis based on machine learning was performed using DNN and SHAP models, allowing identification of key molecular fragments.
No takes yet. Share an insight, caveat, or question.
Silva et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: